Trial Profile
Phase I trial of ICT-107 in glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2016
Price :
$35
*
At a glance
- Drugs ICT 107 (Primary) ; Antineoplastics
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2016 Results published in an ImmunoCellular Therapeutics Media Release
- 21 Nov 2016 According to an ImmunoCellular Therapeutics media release, updated long-term survival data from this trial at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
- 22 Aug 2016 Updated long-term survuval data from this trial will be presented at the Society for NeuroOncology Annual Scintific Meeting 2016, according to an ImmunoCellular Therapeutics media release.